Department for Biochemistry and Clinical Analysis,
Faculty of Pharmacy,
University of Sarajevo
, Sarajevo
, Bosnia and Herzegovina
Faculty of Engineering and Natural Sciences,
Faculty of Engineering and Natural Sciences,
International University of Sarajevo
, Sarajevo
, Bosnia and Herzegovina
Aim To analyse the long-term impact of altered metabolism on the level of mediators of inflammatory response in female patients with type 2 diabetes. Methods This study included 97 female patients with type 2 diabetes and 107 female, nondiabetic control subjects, who were recruited at the Clinical Centre University of Sarajevo and the General Hospital Tešanj. The effects of glycaemic control on markers of inflammatory response represented by C-reactive protein (CRP), fibrinogen, leukocytes, sedimentation rate, and cytokine IL-6 were tested. All subjects were free of evidence of infections, surgery, thyroid disease, polycystic ovarian syndrome, active liver and kidney damage. All biochemical analyses were performed according to standard International Federation of Clinical Chemistry (IFCC) protocols. Results A significant increase of fibrinogen (p<0.001), CRP (p=0.001), interleukin-6 (p=0.013), leukocytes (p<0.001) and sedimentation rate (p=0.008) in diabetic female population compared to control subjects was found. A significant correlation between CRP and haemoglobin A 1c (p=0.035), interleukin-6 and glucose (p=0.032), IL-6 and body mass index (p=0.007) was found. Conclusion Our data suggest that inflammation plays an important role in the pathogenesis of diabetes in female diabetic population. A more detailed study on a far larger number of subjects is needed if they were to be used effectively as biomarkers in the primary prevention of type 2 diabetes in this population.
Donath M, Shoelson S. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011:98–107.
2
Jung U, Choi M. Obesity and its metabolic com n.d.
3
Klein S. Is visceral fat responsible for the metabolic abnormalities associated with obesity?: implications of omentectomy. Diabetes Care 2010:1693–4.
4
Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004:4–7.
5
Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, et al. Proinflammatory cytokines Il-6 and TNF-alpha and the development of inflammation in obese subjects. Eur J Med Res 2010:120–2.
6
Twig G, Afek A, Shamiss A, Derazne E, Tzur D, Gordon B, et al. White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care 2013:276–82.
7
Vozarova B, Weyer C, Lindsay R, Pratley R, Bogardus C, Tataranni P. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002:455–61.
8
Lindsay R, Krakoff J, Hanson R, Bennett P, Knowler W. Gamma globulin levels predict type 2 diabetes in the Pima Indian population. Diabetes 2001:1598–603.
9
Ford E. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol 2002:57–64.
10
Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001:327–34.
11
Kristiansen O, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005:S114-124.
12
Donath M. Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes. Endocrinology 2011:4005–6.
13
Lee C, Adler A, Sandhu M, Sharp S, Forouhi N, Erqou S, et al. Wareham NJ. Association of C-reactive protein with type 2 diabetes: prospective analysis and metaanalysis. Diabetologia 2009:1040–7.
14
Dehghan A, Kardys I, De Maat M, Uitterlinden A, Sijbrands E, Bootsma A, et al. Genetic variation, Creactive protein levels, and incidence of diabetes. Diabetes 2007:872–8.
15
Han T, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M, Haffner S. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002:2016–21.
16
Wang X, Liu B, Ouyang J, Wang Y, Rong D, S, et al. Inflammatory markers andrisk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013:166–75.
17
Nolan C, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011:169–81.
18
Pickup J. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004:813–23.
19
Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay J, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine 2012:136–42.
20
Grossmann V, Schmitt V, Zeller T, Panova-Noeva M, Schulz A, Laubert-Reh D, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 2015:1356–64.
21
Human IL-6 Flex Set 2AD.
22
Dessert J, Bocquet P, Belleville J, Later R, Quincy. An automated immuno-nephelometric method for the quantitative determination of plasma fibrinogen n.d.:215–22.
23
Bo M, Raspo S, Morra F, Cassader M, Isaia G, Poli L. Body fat is the main predictor of fibrinogen levels in healthy non-obese men. Metabolism 2004:984–8.
24
Qi L, Rifai N, Hu F. Interleukin-6 receptor gene, plasma C-reactive protein, and diabetes risk in women. Diabetes 2009:275–8.
25
Hu F, Meigs J, Li T, Rifai N, Manson J. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004:693–700.
26
Thorand B, Baumert J, Doring A, Herder C, Kolb H, Rathmann W, et al. Sex differencesin the relation of body composition to markers of inflammation. Atherosclerosis 2006:216–24.
27
Meisinger C, Thorand B, Schneider A, Stieber J, Doring A, Lowel H. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONI-CA Augsburg cohort study. Arch Intern Med 2002:82–9.
28
Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results fromthe MONICA/KORA Augsburg case-cohort study. Diabetes Care 1984:854–60.
29
Herder C, Carstensen M, Ouwens D. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab 2013:39–50.
30
Roche M, Wang P. Factors associated with a diabetes diagnosis and late diabetes diagnosis for males and females. J Clin Transl Endocrinol 2014:77–84.
31
Global report on diabetes. Diabetes country profiles 2016.
32
Dall T, Narayan K, Gillespie K, Gallo P, Blanchard T, Solcan M, et al. Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines. Popul Health Metr 2014:12.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
